Page 20«..10..19202122..3040..»

She long advocated for heart health. Then her baby’s life was saved by heart surgery – The Gazette

By Jessica Carney, for The Gazette

Julie Fitzpatrick has always been focused on healthy living.

She owns Optimal Wellness and is a physical therapist and wellness specialist at Progressive Rehabilitation Associates in Iowa City. Shes been a volunteer for 13 years with the American Heart Association, focused on spreading awareness of womens health issues.

Im passionate about womens health and wellness, and I believe in what the American Heart Association stands for, she said.

Four years after she became a volunteer, she was pregnant with her daughter, when at the 20-week ultrasound, doctors discovered a heart defect a transposition of the great arteries, meaning the babys aorta and pulmonary artery were reversed.

In the first month of daughter Janies life, the baby had two open-heart surgeries, correcting the defect.

Fifty years ago, Fitzpatrick said, the outcome might not have been as positive.

It made me even more passionate about the American Heart Association and the research they help fund, she said. Our daughter is living proof that the research helps save lives.

Today, Janie is a healthy 9-year-old who is active in gymnastics and volleyball. She has a small heart murmur thats monitored by her doctors, but her activity isnt restricted, and her future looks bright.

We made the decision to trust that shed be well, Fitzpatrick said, explaining she didnt want her daughter thinking her parents were constantly worried about her health.


Fitzpatrick continues to volunteer with the American Heart Association, and she incorporates heart-healthy thinking into both her professional and family life.

Its important to not only know your numbers, like your cholesterol, fasting glucose and BMI, but to do something about it, she said.

She encourages her physical therapy patients to eat healthy, hydrate properly and exercise, even if they have physical limitations. If you have a bad knee, for example, getting in the pool can be a good option, Fitzpatrick said.

Simple changes can have compounded effects if theyre done consistently, she said.

Its not about doing a 30-day program, she said. Its about making it part of your life.

See the rest here:

She long advocated for heart health. Then her baby's life was saved by heart surgery - The Gazette

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Cardiac rehab after heart valve surgery tied to better outcomes – KFGO News

Thursday, October 31, 2019 4:34 p.m. CDT

By Lisa Rapaport

(Reuters Health) - Cardiac rehab, known to be helpful after heart attacks, may also aid recovery from heart valve surgery, a study suggests.

Older adults who got cardiac rehabilitation after heart valve surgery were less likely to be hospitalized or die over the next year than those who didn't get this support, the study found.

Researchers examined data on 41,369 people insured by Medicare, the U.S. health program for individuals 65 and older, who had valve surgery in 2014. Overall, only 43% of them enrolled in medically-supervised cardiac rehab programs focused on things like stress reduction, exercise and heart-healthy living.

Compared to people who didn't go to cardiac rehab, those who did were 34% less likely to be hospitalized within one year of discharge after valve surgery, the study found. And rehab patients were also 61% less likely to die within one year of discharge.

"To our knowledge, this is the first study to evaluate cardiac rehabilitation (CR) utilization among patients undergoing cardiac valve surgery at the national level in the United States," said Dr. Justin Bachmann, senior author of the study and medical director of the cardiopulmonary rehabilitation program at Vanderbilt University Medical Center in Nashville, Tennessee.

Cardiac rehab has previously been found effective for patients recovering from other types of procedures after heart attacks or procedures to place stents to prop open arteries, researchers note in JAMA Cardiology.

"Cardiac rehab includes supervised exercise as well as dietary and smoking cessation counseling," Bachmann said by email. "Management of cardiovascular risk factors (i.e. diet and stopping smoking) as well as improvements in cardiorespiratory fitness translate into improved health."

But not all patients in the study had equal access to cardiac rehab.

Compared to white patients, Asian and Hispanic patients were 64% less likely to get cardiac rehab, while black patients had 40% lower odds.

At the same time, people who had coronary artery bypass grafting in addition to valve surgery were 26% more likely to get cardiac rehab than those who only had valve procedures.

And people living in the Midwest were more than twice as likely to go to cardiac rehab as patients living in southern states.

Half of the patients in the study were at least 73 years old.

One-year mortality rates, excluding people who died while hospitalized for the valve surgery or within 30 days of discharge, were 6.6% overall. Among patients who got cardiac rehab, one-year mortality was 2.2%

The study wasn't designed to prove whether or how cardiac rehab might directly affect patient outcomes, nor did it examine why some patients might not have been offered cardiac rehab or chose not to enroll.

Even so, the results underscore the importance of discussing options for cardiac rehab, when possible before surgery so services will be lined up when they're needed, said Dr. Randal Thomas, co-author of an editorial accompanying the study and medical director of cardiac rehabilitation at the Mayo Clinic in Rochester, Minnesota.

"They will recover quicker, feel better, function better, and live longer as a result," Randal said by email. "If a center-based program is not available near them, they should ask about the options for a home-based cardiac rehabilitation program that would be available to them instead."

SOURCE: and JAMA Cardiology, online October 23, 2019.

Read more here:

Cardiac rehab after heart valve surgery tied to better outcomes - KFGO News

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Mild cognitive impairments show improvement with healthy lifestyle – Tyler Morning Telegraph

Can there be anything more highly recommended and universally agreed upon than regular exercise and healthy nutrition for a sound mind and sound body? If there is, its the best-kept secret around. In short, diet and exercise are no-brainers, especially when it comes to the brain.

Today, we have a better understanding of the positive effects of exercise and the foods we eat on mental health. But what about cognitive health our ability to remember things, our capacity to easily access, retrieve, interpret and articulate stored information from our brain? When that declines, can regular exercise and healthy eating help that, too? New research suggests that it can.

Mild cognitive impairment is the term given to a condition where a slight but noticeable decline in cognitive abilities takes place. There are two types of MCI: (1) amnestic MCI affects a persons recall and ability to remember things such as appointments and recent events and (2) nonamnestic MCI includes thinking skills, such as the ability to make decisions and solve complex tasks. A person with MCI has an increased risk of developing Alzheimers disease.

In a study published in 2018, researchers at Duke University Medical Center reported that an experimental group of older adults living with MCI (but not dementia) who participated in six months of thrice-weekly aerobic exercise, and followed the DASH diet (Dietary Approaches to Stop Hypertension), experienced substantial improvement in their executive functioning. Executive functioning refers to mental activities processed in the frontal lobe of the brain including remembering things, organizing tasks, managing time, paying attention and thinking creatively. Other groups in this randomized investigation that only followed the diet, only exercised or were only given health education material to study did not demonstrate this level of improvement to their MCI condition. In fact, the study demonstrated that improved planning skills as a result of the intervention rivaled skills of those who are eight years younger.

So, how can you apply this information to your own life? It is essential that you recognize that making changes to your lifestyle can have a dramatic and positive effect on your brain health (and overall health, of course).

For more information, contact Claudann Jones, Smith County Extension agent for family and community health, at 903-590-2980 or email at Like our Facebook page: Texas A&M AgriLife Extension Service Smith County.

Here is the original post:

Mild cognitive impairments show improvement with healthy lifestyle - Tyler Morning Telegraph

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Medical Wellness Market Competitive Research And Precise Outlook 2019 To 2024 – Maxi Wire

The Medical Wellness market will register a 5.4% CAGR in terms of revenue, the global market size will reach US$ 5776600 million by 2024, from US$ 4681700 million in 2019.

The Medical Wellness Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2024. The Medical Wellness Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). Report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries. This Medical Wellness Market study provides comprehensive data which enhances the understanding, scope and application of this report.

Top Companies in the Global Medical Wellness Market: Massage Envy, HEALING HOTELS OF THE WORLD, Steiner Leisure Limited, Fitness World, Universal Companies, World Gym, Nanjing Zhaohui, Beauty Farm, Edge Systems LLC, VLCC Wellness Center, Arashiyu Japanese Foot Spa, WTS International, Enrich Hair & Skin, Golds Gym International, The Body Holiday, Kaya Skin Clinic, Guardian Lifecare, Kayco Vivid, Bon Vital, Biologique Recherche, Healthkart.

Wellness describes itself as complete physical mental and social well-being. It comprises all the components used to lead a healthy life. Wellness is multidirectional and constitutes social, emotional, physical, spiritual, intellectual and emotional wellbeing.

The classification of Medical Wellness includes Complementary and Alternative Medicine, Beauty Care and Anti-Aging, Preventative & Personalized Medicine and Public Health, Healthy Eating, Nutrition & Weight Loss, Rejuvenation and Other, and the proportion of Beauty Care and Anti-Aging in 2017 is about 24.4%.Medical Wellness is widely sales through Franchise, Company Owned Outlets The most proportion of Medical Wellness is sales through Franchise, and the proportion in 2017 is 65.9%.North America is the largest consumption place, with a consumption market share nearly 35.3% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 32.4%.

This report segments the global Medical Wellness Market on the basis ofTypesare:Complementary and Alternative MedicineBeauty Care and Anti-AgingPreventative & Personalized Medicine and Public HealthHealthy Eating, Nutrition & Weight LossRejuvenationOther

On The basis Of Application, the Global Medical Wellness Market is Segmented into:FranchiseCompany Owned Outlets

Regions Are covered By Medical Wellness Market Report 2019 To 2024.North America, Europe, China, Japan, Southeast Asia, India, North America (USA, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia).

Detailed overview of Medical Wellness Market Changing Medical Wellness market dynamics of the industry In-depth market segmentation by Type, Application, etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Medical Wellness Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth.

Strategic Developments: The custom analysis gives the key strategic developments of the Medical Wellness market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the main rivals working in the market on a worldwide and provincial scale.Market Features: The report includes market highlights, limit, limit use rate, income, value, net, generation, creation rate, utilization, import, trade, supply, request, cost, piece of the overall industry, CAGR, and gross edge. Moreover, the report offers a far reaching investigation of the market elements and their most recent patterns, alongside market fragments and sub-portions.Analytical Tools: The Global Medical Wellness Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

Free country Level analysis for any 5 countries of your choice.Free Competitive analysis of any 5 key market players.Free 40 analyst hours to cover any other data point.

Market Insights Reports is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Irfan Tamboli (Sales Manager) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687[emailprotected] | [emailprotected]

Read this article:

Medical Wellness Market Competitive Research And Precise Outlook 2019 To 2024 - Maxi Wire

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Global Moringa Ingredients Market: Key companies Profile, their market Share and other important parameters – Market Research Writeup

Moringa ingredients derived from moringa plant are extremely nutritious and has many health uses. Moringa is popular in India, as drumsticks. All the parts of moringa tree can be used as ingredients for moringa products such as seeds can be used for the production of oil, the pod is used in medicines and also as human consumption, furthermore, the leaf can be used as animal feed and also in various health products. Moringa flower contains D-glocuse, wax, sucrose, and is rich in potassium, calcium, and nine amino acids. The tea made with moringa flowers is considered to have nutritional benefits and to be a powerful medicine. Moringa leaves contains many anti-aging compounds that scale back the consequences of oxidative stress and inflammation, including vitamin C, polyphenols, beta-carotene, quercetin, and chlorogenic acid. Moringa helps in reduction of tiredness, fatigue, and boosts the immune system. Moringa, as a rich source of calcium, helps in the normal digestive system function.

The Moringa market is segmented on the basis of its products such as Moringa leaf, Moringa Oil, and Moringa fruits/pods. Moringa leaves contain excessive nutritional values and amino acids and the extracts of Moringa leaves can be eaten fresh, cooked, or dried. There are numerous ways to include the Moringa leaf powder into the eating routine. It can be sprinkled on food, mixed with tea or taken as a capsule, and cooking salads.

The moringa ingredients market is segmented on the basis of applications, products, and region. On the basis of applications moringa ingredients market is segmented into different industries such as food industry, cosmetic industry, pharmaceutical industry, personal care industry, and others. Other include biofuel, pulp and paper industry etc. In pharmaceuticals, application of moringa ingredients are found in leaf syrups, dietary supplements, capsules and tablets, oil, etc.

Globally, Asia Pacific region is the largest exporter of Moringa products. India is the most advanced supplier of Moringa Leaf, Moringa Oil, Moringa Fruits, and Seeds, but African and American countries are also increasing their production. The Moringa tree is native to India and grown in Africa, Asia Pacific Regions. Some of the key supplier countries of Moringa products in Asia Pacific regions are Philippines, Cambodia, Bangladesh, and Afghanistan.

Access Report Details at:

The global Moringa Ingredients market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

This report focuses on Moringa Ingredients volume and value at global level, regional level and company level. From a global perspective, this report represents overall Moringa Ingredients market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

Key companies profiled in Moringa Ingredients Market report are Ancient GreenFields, The Mito Group, Santan India, Jaw Der Develop,Himalaya Healthcare, Prosper and more in term of company basic information, Product Introduction, Application, Specification, Production, Revenue, Price and Gross Margin (2014-2019), etc.

Purchase this Premium Report at:

Table of Content

1 Moringa Ingredients Market Overview

2 Global Moringa Ingredients Market Competition by Manufacturers

3 Global Moringa Ingredients Production Market Share by Regions

4 Global Moringa Ingredients Consumption by Regions

5 Global Moringa Ingredients Production, Revenue, Price Trend by Type

6 Global Moringa Ingredients Market Analysis by Applications

7 Company Profiles and Key Figures in Moringa Ingredients Business

8 Moringa Ingredients Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Global Moringa Ingredients Market Forecast

12 Research Findings and Conclusion

13 Methodology and Data Source

See original here:

Global Moringa Ingredients Market: Key companies Profile, their market Share and other important parameters - Market Research Writeup

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Low T Therapy After Prostate CA Surgery Appears Safe – MedPage Today

NASHVILLE -- Testosterone replacement remains controversial in men who have been treated for prostate cancer, but new data from New York's Memorial Sloan Kettering Cancer Center (MSKCC) reported here may provide some reassurance that "low T" treatments at least are safe in this population.

Among 1,563 men treated for high-risk prostate cancer at MSKCC and followed for up to 15 years, cancer recurrence rates were similar in men with low testosterone levels who took androgen replacement therapy to those in men with untreated low T and men with normal testosterone levels, reported Helen Bernie, DO, of Indiana University Health in Indianapolis.

And in a related study that included men with Gleason 6 and 7 prostate cancers, treated with radical prostatectomy, testosterone replacement begun 9 months after surgery showed no evidence of harm in ongoing follow-up (mean treatment duration of just over 3 years thus far), according to MSKCC's Carolyn Salter, MD.

Both studies were presented at the Sexual Medicine Society of North America's annual meeting.

"We believe that we have shown that testosterone therapy is not dangerous in these men, which has obvious clinical implications," said Salter, who added that -- given the absence of long-term safety data on testosterone treatment in prostate cancer patients -- larger and longer multicenter studies are still needed.

Bernie, who participated in the recurrence-rate study as a fellow at MSKCC, explained that it involved patients who underwent radical prostatectomy with high-risk prostate cancer, defined as Gleason 6/7 with unfavorable pathology, with positive surgical margins, lymph node involvement, and seminal vesicle involvement. Men with Gleason scores of 8 or higher with any pathology status were also eligible for recruitment. Biochemical recurrence was defined as a PSA level of 0.1 ng/mL.

Men were considered to have low testosterone if they had two or more morning blood test readings of less than 300 ng/dL.

In all, 1,119 (72%) men experienced biochemical recurrence at some point in 15-year follow-up, including 67% in the normal testosterone group, 80% in the untreated low T group, and 41% of men in the group with low T treated with replacement therapy.

After covariate adjustment, neither low T itself nor testosterone replacement therapy were associated with biochemical recurrence.

"These data suggest that patients with high-risk prostate cancer with low testosterone who were treated with testosterone therapy had no higher rates of biochemical recurrence," Bernie said.

Salter's study followed 360 men who have been prescribed testosterone therapy in the months following radical prostatectomy. To be considered for therapy, men had to have organ-confined disease and undetectable PSA post surgery. Men who opted for treatment had their testosterone doses titrated to achieve a serum level of 500-600 ng/dL, and PSA was checked every 6 months.

The men continue to be followed, and Salter noted that the mean time on testosterone therapy at last follow-up was 38 months. A single patient had a PSA recurrence, roughly 2.5 years after surgery.

Responding to an audience question after the presentations, MSKCC urologic surgeon John P. Mulhall, MD -- who helped establish the center's testosterone replacement therapy program more than a decade ago -- acknowledged that the treatment's long-term safety hasn't been completely established.

"We don't have enough data, but what we do have is a negotiated decision with our patients," Mulhall said. "We document in their chart that they have been made aware of the absence of long-term safety data, and that they accept that."

The researchers in both studies reported no funding source nor relevant disclosures.


Read the original here:
Low T Therapy After Prostate CA Surgery Appears Safe - MedPage Today

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars – P&T Community

PALM BEACH, Florida, Oct. 29, 2019 /PRNewswire/ -- There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And these new treatment are hope they could be key to combating viral infections such as, bacteria, viruses, fungi,HBV, hepatitis C, Influenza, HSV, Human papillomavirus and parasites account for approximately 15million deaths worldwide, with acute respiratory infections and human immunodeficiency virus (HIV) being the leading causes. The National Institutes for Health NCBI Center for Biotechnology Information (NCBI) reports: "Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery." Mentioned in today's commentary includes: TG Therapeutics, Inc. (NASDAQ: TGTX), NanoViricides, Inc. (NYSE: NNVC), Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Clovis Oncology, Inc. (NASDAQ: CLVS), Pfizer Inc. (NYSE: PFE).

Nanoparticle-based delivery systems present new opportunities to overcome challenges associated with conventional drug therapies and have therefore attracted enormous interest in the treatment of viral infections. Nanomaterials can be engineered to incorporate conventional antiviral properties with those modifications that are unique to nanosystems (ultra small and controllable size, large surface area to volume ratio, and the ability to tailor the surface with the possibility of multi-functionalization). This is undoubtedly a promising tool for biomedical research and clinical use.

One of the more active companies in the industry includes NanoViricides, Inc. (NYSE American: NNVC). NanoViricides,a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, on October 9, 2019 announced that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials.

The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. These studies and analyses are part of the required general safety and toxicology studies that will go into an Investigational New Drug (IND) Application to the US FDA.

NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.

The company feels that the market size for its immediate target drugs in the HerpeCide program is variously estimated into Billions to tens of Billions of Dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

NanoViricidesalso released a report this past August that its first drug candidate, NV-HHV-101, is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

The Company has previously found that NV-HHV-101 was safe and well tolerated in non-GLP safety/toxicology studies. The GLP studies are an expanded version of the non-GLP studies, with extended treatment, larger number of subjects, and stringent operational requirements as specified by the current Good Laboratory Practices guidelines for such studies.

Additional studies required for the Safety and Toxicology datasets for filing an IND are in progress.

The Company anticipates advancing NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication, assuming that these studies are successful. The Company also continues to evaluate this broad-spectrum drug candidate as well as certain variations based on the same candidate, for the treatment of other herpesviruses, namely HSV-1 cold sores and HSV-2 genital herpes. The market size for its immediate target drugs in the HerpeCide program is variously estimated into billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

In addition, the Company also recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company has reported that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

NanoViricides' current programs target a potential market opportunity of over $20 Billion. Investors are urged to view an informative video interview with Anil R. Diwan, PhD, President and Executive Chairman, who was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. Click here to access the video interview.

In other biotech news in the markets this week:

TG Therapeutics, Inc.(NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company's novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company's prespecified ORR target of 40-50%. Importantly, umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports.

The Company plans to present the data at a future medical conference as well as discuss the data with the U.S. Food and Drug Administration (FDA).

Matinas BioPharma Holdings, Inc.(NYSE AMER: MTNB), a clinical stage biopharmaceutical company, this month announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

"We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis," commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas.

Clovis Oncology, Inc.(NASDAQ: CLVS) this month announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.

"Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting," said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer.

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.Third-Quarter 2019 Revenues of $12.7 Billion, Reflecting 3% Operational Decline; Excluding the Impact from Consumer Healthcare, Third-Quarter 2019 Revenues were Flat Operationally - See the full financial reporting at:

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates and, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact -+1(561)325-8757

The rest is here:
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars - P&T Community

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN – Dove Medical Press

Yanhai Xi,1,* Tingwang Jiang,2,* Birendra Chaurasiya,3 Yanyan Zhou,1 Jiangmin Yu,1 Jiankun Wen,1 Yan Shen,3 Xiaojian Ye,1 Thomas J Webster4

1Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, Peoples Republic of China; 2Department of Immunology and Microbiology, Institution of Laboratory Medicine of Changshu, Changshu, Jiangsu 215500, Peoples Republic of China; 3Department of Pharmaceutics, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, China Pharmaceutical University, Nanjing, Peoples Republic of China; 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA

*These authors contributed equally to this work

Correspondence: Xiaojian YeDepartment of Spine Surgery, Changzheng Hospital, Second Military Medical University, 360 Huntington Avenue, Shanghai, MA 200003, Peoples Republic of ChinaTel +86 1 381 734 6934Email

Thomas J WebsterDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USATel +1 617 373 6585Email

Abstract: Ankylosing spondylitis (AS) is a complex disease characterized by inflammation and ankylosis primarily at the cartilagebone interface. The disease is more common in young males and risk factors include both genetic and environmental. While the pathogenesis of AS is not completely understood, it is thought to be an immune-mediated disease involving inflammatory cellular infiltrates, and human leukocyte antigen-B27. Currently, there is no specific diagnostic technique available for this disease; therefore conventional diagnostic approaches such as clinical symptoms, laboratory tests and imaging techniques are used. There are various review papers that have been published on conventional treatment approaches, and in this review work, we focus on the more promising nanomedicine-based treatment modalities to move this field forward.

Keywords: ankylosing spondylitis, pathogenesis, genetic factors, environmental factors, treatment approaches

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read this article:
Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Comprehensive Study on Healthcare Nanotechnology (Nanomedicine) Market 2019 | Trends, Drivers, Strategies, Applications and Competitive Landscape…

New report on Healthcare Nanotechnology (Nanomedicine) Market 2019 focuses on the growth opportunities, which will help the Healthcare Nanotechnology (Nanomedicine) market to expand operations in the existing markets. Healthcare Nanotechnology (Nanomedicine) market research study is significant for manufacturers in the Healthcare Nanotechnology (Nanomedicine) market, including industry stakeholders, distributors, suppliers, and investors, and it can also help them understand applicable strategies to grow in the Healthcare Nanotechnology (Nanomedicine) market.

In Healthcare Nanotechnology (Nanomedicine) Market Report, Following Companies Are Covered:

Healthcare Nanotechnology (Nanomedicine) Market Report Provides Comprehensive Analysis of:

For More Information or Query or Customization Before Buying, Visit at

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reasons for Buying Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for single user license)

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2019-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study



4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd


Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Superphosphate Market 2019 Global Industry Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2023

Infusion Pump Market Segmentation 2019-2023 Covers Price, Sales, Revenue, Growth Rate Details by Regions, Types, and Applications

Global Nut Meals Market 2019-2022 Segmentation Based on Product, Application and Region

Global Silicon Wafers Market 2019 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2025

Comprehensive Study on Healthcare Nanotechnology (Nanomedicine) Market 2019 | Trends, Drivers, Strategies, Applications and Competitive Landscape...

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Briggs undergrad researcher wins award at international conference – MSUToday

For senior Hasaan Hayat, a Lyman Briggs student with dual majors in neuroscience and human biology, the opportunity to work in a cutting-edge laboratory as an undergraduate researcher both confirmed his interests in technology and medicine and helped illuminate his career path.

For about a year, Hayat has been contributing to research in the lab of Ping Wang, an affiliate with MSUs Precision Health Program, or PHP. Precision medicine, a component of PHP, is a fairly recent field of biomedicine. This field develops personalized, patient-specific therapies and treatments, often incorporating tools like molecular imaging, nanoparticle technology and artificial intelligence to produce better outcomes for patients.

Through research like that of Wang, tools and technologies can be developed to detect disease sooner and treat it earlier, achieving better outcomes and reducing healthcare costs. PHP at MSU aims to transform the approach to healthcare from reactive to proactive by focusing on disease prediction, prevention and early detection.

Hayat has been interested in technology and human biology for as long as he can remember. After he joined Wangs lab, he became especially intrigued by the use of artificial intelligence, or AI, in the field of precision medicine.

As a child, I only dreamed of working on such technology myself due to its complexity and mass potential, but I also feared it, thanks to dystopian films such asTerminatorandiRobotwhere the sentient machine is always portrayed as the bad guy, he said. However, I find that AI can be a crucial, beneficial tool for analysis and monitoring of patients in a more modern field of medicine, specifically in oncology, radiology and stem-cell transplants.

Researching in Wangs lab has provided Hayat a unique platform to investigate the intersection of technology and biology. One specific study involved the application of deep learning in non-invasive imaging for monitoring tumor response to chemotherapy.

With help from Wang and Moore, Hayat put together an abstract of his work titled, Molecular imaging and analysis of uMUC1 expression levels in response to chemotherapy in an orthotopic murine model of ovarian cancer, and submitted it to the World Molecular Imaging Congress 2019, or WMIC 2019, in Montreal, Canada.

The WMIC 2019 program committee invited Hayat to present this research as an oral presentation, which is a high honor for the attendees. Hayats paper was one of the highest-rated abstracts at the conference and he won the Student Travel Award.

Hayat was grateful and energized by the experience of presenting at an international research conference.

The congress was phenomenal. I was able to hear about some amazing research and innovations in the field of medicine and molecular imaging/biology, he said. Networking with knowledgeable individuals from top institutions all over the world was a highlight of the event, and I am thankful to PHP and MSU for this opportunity.

Hayat was originally drawn to MSU for its many research opportunities, and specifically to Lyman Briggs College, because of its solid foundations in science.

I admire Lyman Briggs for its creative and innovative approach to STEM fields, and its focus on preparing students for success in graduate school, he said. The faculty at Lyman Briggs are very supportive and ensure that students have a clear understanding of core scientific concepts.

As for the future, his work with the Precision Health Program is inspiring him to go to medical school.

I aim to pursue an M.D.-Ph.D. after I graduate, a decision that has been heavily reinforced by the research I am doing at the Precision Health Program, and my mentor and PI, Dr. Wang, who himself is an M.D.-Ph.D. I salute the cutting-edge work that is performed here, he said. In the future, it is a dream and vision of mine to bring novel, innovative therapies and technologies such as AI and nanomedicine to the clinic in order to provide tools for physicians to use and to improve patient outcomes.

Visit link:
Briggs undergrad researcher wins award at international conference - MSUToday

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Page 20«..10..19202122..3040..»